212 related articles for article (PubMed ID: 29708591)
1. Alcohol, smoking, and risk of Her2-overexpressing and triple-negative breast cancer relative to estrogen receptor-positive breast cancer.
Baglia ML; Cook LS; Mei-Tzu C; Wiggins C; Hill D; Porter P; Li CI
Int J Cancer; 2018 Oct; 143(8):1849-1857. PubMed ID: 29708591
[TBL] [Abstract][Full Text] [Related]
2. Body mass index and risk of luminal, HER2-overexpressing, and triple negative breast cancer.
Chen L; Cook LS; Tang MT; Porter PL; Hill DA; Wiggins CL; Li CI
Breast Cancer Res Treat; 2016 Jun; 157(3):545-54. PubMed ID: 27220749
[TBL] [Abstract][Full Text] [Related]
3. Reproductive Factors and Risk of Luminal, HER2-Overexpressing, and Triple-Negative Breast Cancer Among Multiethnic Women.
Chen L; Li CI; Tang MT; Porter P; Hill DA; Wiggins CL; Cook LS
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1297-304. PubMed ID: 27307466
[TBL] [Abstract][Full Text] [Related]
4. Active smoking and the risk of estrogen receptor-positive and triple-negative breast cancer among women ages 20 to 44 years.
Kawai M; Malone KE; Tang MT; Li CI
Cancer; 2014 Apr; 120(7):1026-34. PubMed ID: 24515648
[TBL] [Abstract][Full Text] [Related]
5. Alcohol, Smoking, and Risks of Breast Cancer Recurrence and Mortality among Women with Luminal, Triple-Negative, and HER2-Overexpressing Breast Cancer.
Loroña NC; Othus M; Malone KE; Linden HM; Tang MC; Li CI
Cancer Epidemiol Biomarkers Prev; 2024 Feb; 33(2):288-297. PubMed ID: 38019269
[TBL] [Abstract][Full Text] [Related]
6. Recent Use of Oral Contraceptives and Risk of Luminal B, Triple-Negative, and HER2-Overexpressing Breast Cancer.
Lorona NC; Cook LS; Tang MC; Hill DA; Wiggins CL; Li CI
Horm Cancer; 2019 Jun; 10(2-3):71-76. PubMed ID: 30989580
[TBL] [Abstract][Full Text] [Related]
7. Height, body mass index (BMI), BMI change, and the risk of estrogen receptor-positive, HER2-positive, and triple-negative breast cancer among women ages 20 to 44 years.
Kawai M; Malone KE; Tang MT; Li CI
Cancer; 2014 May; 120(10):1548-56. PubMed ID: 24500704
[TBL] [Abstract][Full Text] [Related]
8. Alcohol, Physical Activity, Smoking, and Breast Cancer Subtypes in a Large, Nested Case-Control Study from the Norwegian Breast Cancer Screening Program.
Ellingjord-Dale M; Vos L; Hjerkind KV; Hjartåker A; Russnes HG; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Cancer Epidemiol Biomarkers Prev; 2017 Dec; 26(12):1736-1744. PubMed ID: 28877889
[No Abstract] [Full Text] [Related]
9. Pattern of hormone receptors and human epidermal growth factor receptor 2 status in sub-Saharan breast cancer cases: Private practice experience.
Nwafor CC; Keshinro SO
Niger J Clin Pract; 2015; 18(4):553-8. PubMed ID: 25966732
[TBL] [Abstract][Full Text] [Related]
10. Parity, hormones and breast cancer subtypes - results from a large nested case-control study in a national screening program.
Ellingjord-Dale M; Vos L; Tretli S; Hofvind S; Dos-Santos-Silva I; Ursin G
Breast Cancer Res; 2017 Jan; 19(1):10. PubMed ID: 28114999
[TBL] [Abstract][Full Text] [Related]
11. Epidemiological risk factors associated with inflammatory breast cancer subtypes.
Atkinson RL; El-Zein R; Valero V; Lucci A; Bevers TB; Fouad T; Liao W; Ueno NT; Woodward WA; Brewster AM
Cancer Causes Control; 2016 Mar; 27(3):359-66. PubMed ID: 26797453
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of triple negative breast cancers.
Gierach GL; Burke A; Anderson WF
Breast Dis; 2010; 32(1-2):5-24. PubMed ID: 21965309
[TBL] [Abstract][Full Text] [Related]
13. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society.
Iwase H; Kurebayashi J; Tsuda H; Ohta T; Kurosumi M; Miyamoto K; Yamamoto Y; Iwase T
Breast Cancer; 2010 Apr; 17(2):118-24. PubMed ID: 19466512
[TBL] [Abstract][Full Text] [Related]
15. Survival outcome of weak estrogen/progesterone receptor expression in HER2 negative breast cancer is similar to triple negative breast cancer.
Liao GS; Dai MS; Hsu HM; Chu CH; Hong ZJ; Fu CY; Chou YC; Huang TC; Yu JC
Eur J Surg Oncol; 2017 Oct; 43(10):1855-1861. PubMed ID: 28756019
[TBL] [Abstract][Full Text] [Related]
16. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
[TBL] [Abstract][Full Text] [Related]
17. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
18. Alcohol intake and risk of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis of epidemiological studies.
Suzuki R; Orsini N; Mignone L; Saji S; Wolk A
Int J Cancer; 2008 Apr; 122(8):1832-41. PubMed ID: 18067133
[TBL] [Abstract][Full Text] [Related]
19. Alcohol intake and invasive breast cancer risk by molecular subtype and race in the Carolina Breast Cancer Study.
Williams LA; Olshan AF; Tse CK; Bell ME; Troester MA
Cancer Causes Control; 2016 Feb; 27(2):259-69. PubMed ID: 26705260
[TBL] [Abstract][Full Text] [Related]
20. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
